These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 24472170)

  • 1. Microenvironmental pH-modification to improve dissolution behavior and oral absorption for drugs with pH-dependent solubility.
    Taniguchi C; Kawabata Y; Wada K; Yamada S; Onoue S
    Expert Opin Drug Deliv; 2014 Apr; 11(4):505-16. PubMed ID: 24472170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microenvironmental pH modulation in solid dosage forms.
    Badawy SI; Hussain MA
    J Pharm Sci; 2007 May; 96(5):948-59. PubMed ID: 17455349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving Dissolution Behavior and Oral Absorption of Drugs with pH-Dependent Solubility Using pH Modifiers: A Physiologically Realistic Mass Transport Analysis.
    Salehi N; Kuminek G; Al-Gousous J; Sperry DC; Greenwood DE; Waltz NM; Amidon GL; Ziff RM; Amidon GE
    Mol Pharm; 2021 Sep; 18(9):3326-3341. PubMed ID: 34428047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Microenvironmental pH Modulation on the Dissolution Rate and Oral Absorption of the Salt of a Weak Acid - Case Study of GDC-0810.
    Hou HH; Jia W; Liu L; Cheeti S; Li J; Nauka E; Nagapudi K
    Pharm Res; 2018 Jan; 35(2):37. PubMed ID: 29380076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulation of solid dosage forms to overcome gastric pH interaction of the factor Xa inhibitor, BMS-561389.
    Badawy SI; Gray DB; Zhao F; Sun D; Schuster AE; Hussain MA
    Pharm Res; 2006 May; 23(5):989-96. PubMed ID: 16715389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulation and Pharmacokinetic Evaluation of Polymeric Dispersions Containing Valsartan.
    Chella N; Daravath B; Kumar D; Tadikonda RR
    Eur J Drug Metab Pharmacokinet; 2016 Oct; 41(5):517-26. PubMed ID: 26156887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
    Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
    Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
    Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fabrication and evaluation of pH-modulated solid dispersion for telmisartan by spray-drying technique.
    Marasini N; Tran TH; Poudel BK; Cho HJ; Choi YK; Chi SC; Choi HG; Yong CS; Kim JO
    Int J Pharm; 2013 Jan; 441(1-2):424-32. PubMed ID: 23174408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. pH modulation: a mechanism to obtain pH-independent drug release.
    Bassi P; Kaur G
    Expert Opin Drug Deliv; 2010 Jul; 7(7):845-57. PubMed ID: 20509776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced dissolution and bioavailability of Nateglinide by microenvironmental pH-regulated ternary solid dispersion: in-vitro and in-vivo evaluation.
    Wairkar S; Gaud R; Jadhav N
    J Pharm Pharmacol; 2017 Sep; 69(9):1099-1109. PubMed ID: 28590055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug dissolution: significance of physicochemical properties and physiological conditions.
    Jambhekar SS; Breen PJ
    Drug Discov Today; 2013 Dec; 18(23-24):1173-84. PubMed ID: 24042023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
    Fei Y; Kostewicz ES; Sheu MT; Dressman JB
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melt dispersion granules: formulation and evaluation to improve oral delivery of poorly soluble drugs - a case study with valsartan.
    Chella N; Tadikonda R
    Drug Dev Ind Pharm; 2015 Jun; 41(6):888-97. PubMed ID: 24796274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Biopredictive In Vitro Comparison of Oral Locally Acting Mesalazine Formulations by a Novel Dissolution Model for Assessing Intraluminal Drug Release in Individual Subjects.
    Karkossa F; Klein S
    J Pharm Sci; 2018 Jun; 107(6):1680-1689. PubMed ID: 29499277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissolution enhancement of atorvastatin calcium by co-grinding technique.
    Prabhu P; Patravale V
    Drug Deliv Transl Res; 2016 Aug; 6(4):380-91. PubMed ID: 26712124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting in vivo absorption behavior of oral modified release dosage forms containing pH-dependent poorly soluble drugs using a novel pH-adjusted biphasic in vitro dissolution test.
    Heigoldt U; Sommer F; Daniels R; Wagner KG
    Eur J Pharm Biopharm; 2010 Sep; 76(1):105-11. PubMed ID: 20472059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications.
    Kawabata Y; Wada K; Nakatani M; Yamada S; Onoue S
    Int J Pharm; 2011 Nov; 420(1):1-10. PubMed ID: 21884771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel formulations of dipyridamole with microenvironmental pH-modifiers for improved dissolution and bioavailability under hypochlorhydria.
    Taniguchi C; Inoue R; Kawabata Y; Yamashita K; Wada K; Yamauchi Y; Yamada S; Onoue S
    Int J Pharm; 2012 Sep; 434(1-2):148-54. PubMed ID: 22643223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advantage of the Dissolution/Permeation System for Estimating Oral Absorption of Drug Candidates in the Drug Discovery Stage.
    Miyaji Y; Fujii Y; Takeyama S; Kawai Y; Kataoka M; Takahashi M; Yamashita S
    Mol Pharm; 2016 May; 13(5):1564-74. PubMed ID: 27031624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.